Latest News

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGE...

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA®

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Heal...

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcar

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufact...

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demo...

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstra

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Out...

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook

Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro F...

Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Footba

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in No...

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in Novembe

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as ...

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Tre

Teva Releases Q3 2025 Aide Memoire

Teva Releases Q3 2025 Aide Memoire

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on Novembe...

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5,

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement...

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapi...

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LA

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine...

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy